SCHEMBL101926

SCHEMBL101926

CC(C)c1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
MAPT P10636 4/20 0.64
KDM4E B2RXH2 3/20 0.64
GAA P10253 3/20 0.64
PTK2B Q14289 2/20 0.64
ADRA2C P18825 1/20 0.64
GFER P55789 1/20 0.64
KMT2A Q03164 1/20 0.64
ESR2 Q92731 1/20 0.64
HTR3A P46098 1/20 0.52
SIRT6 Q8N6T7 1/20 0.50
SIGMAR1 Q99720 1/20 0.49
KDM1A O60341 1/20 0.48
CHKA P35790 1/20 0.47
PANK3 Q9H999 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
MAPK1 P28482 3/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15247182 0.93 CHKA (0.58) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL20251137 0.91 MAPT (0.51) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL20884653 0.88 ALDH1A1 (0.50) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL2427568 0.84 MAPT (0.60) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL18509241 0.84 MAPT (0.55) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL20354340 0.84 ALDH1A1 (0.55) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL14146896 0.84 MAPT (0.60) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL21388627 0.84 MAPT (0.60) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL3588583 0.84 MAPT (0.55) ALDH1A1MAPTKDM4EGAAPTK2B
SCHEMBL15247281 0.84 MAPT (0.55) ALDH1A1MAPTKDM4EGAAPTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
EP-4289835-A1 CDK INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2023-12-13 EP disclosed
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-11-28 US disclosed
US-20230374008-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2023-11-23 US disclosed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US disclosed
US-11779650-B2 Pyrrolobenzodiazepine-antibody conjugates MEDIMMUNE LIMITED (GB) 2023-10-10 US disclosed
US-20080261988-A1 IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-10-23 US disclosed
US-20080261988-A1 IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS SUPERGEN, INC. (US) 2008-10-23 US disclosed
US-20080227789-A1 DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
EP-1313713-B1 4-PYRIMIDINAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS ORTHO MCNEIL PHARM INC (US) 2008-06-11 EP disclosed
WO-2007140222-A2 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2007-12-06 WO disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 US disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 US disclosed
US-20070072851-A1 Pyrazolopyridine and pyrazolopyrimidine compounds AMGEN INC. (US) 2007-03-29 US disclosed
US-20070072851-A1 Pyrazolopyridine and pyrazolopyrimidine compounds AMGEN INC. (US) 2007-03-29 US disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827640-B2 Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators PDE4A, PDE4B, PDE5A ALDH1A1 983/4885MAPT 4661/4885KDM4E 2287/4885
US-11779650-B2 Pyrrolobenzodiazepine-antibody conjugates IL2RA, CD4, IL2 ALDH1A1 2032/4885MAPT 1007/4885KDM4E 2257/4885
US-20080261988-A1 IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 ALDH1A1 1612/4885MAPT 4202/4885KDM4E 1471/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 ALDH1A1 3235/4885MAPT 3127/4885KDM4E 1689/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 ALDH1A1 4740/4885MAPT 3895/4885KDM4E 3143/4885
US-20230374008-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 ALDH1A1 543/4885MAPT 1168/4885KDM4E 4157/4885
US-20080227789-A1 DIAMINOTHIAZOLES USEFUL AS AXL INHIBITORS AXL, TYRO3, MERTK ALDH1A1 3782/4885MAPT 2130/4885KDM4E 4224/4885
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B ALDH1A1 3226/4885MAPT 3813/4885KDM4E 360/4885
US-20070072851-A1 Pyrazolopyridine and pyrazolopyrimidine compounds LCK, MAP4K5, TPMT ALDH1A1 2379/4885MAPT 264/4885KDM4E 2744/4885
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF PDXK, CMPK1, GCK ALDH1A1 1593/4885MAPT 3916/4885KDM4E 2176/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 ALDH1A1 2379/4885MAPT 2433/4885KDM4E 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.